Annapaola Mariniello1, Eleonora Ghisoni2,3, Luisella Righi1, Annamaria Catino4, Rita Chiari5, Alessandro Del Conte6, Fausto Barbieri7, Fabiana Cecere8, Alain Gelibter9, Matteo Giajlevra10, Hector Soto Parra11, Clizia Zichi1, Massimo DI Maio12, Giorgio Valabrega13,3, Silvia Novello1. 1. Department of Oncology, University of Torino at San Luigi University Hospital, Orbassano, Italy. 2. Department of Oncology, University of Torino, Turin, Italy. 3. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. 4. Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. 5. Department of Medical Oncology, University of Perugia at Santa Maria della Misericordia Hospital, Perugia, Italy. 6. Centro di Riferimento Oncologico (CRO) - IRCCS, Oncology Unit, Pordenone, Italy. 7. Department of Oncology and Hematology, University-Hospital of Modena and Reggio Emilia, Modena, Italy. 8. Careggi University Hospital, Medical Oncology Unit, Department of Oncology, Florence, Italy. 9. Sapienza University of Rome at Policlinico Umberto I, Oncology Unit, Rome, Italy. 10. CHU Grenoble Alpes, Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, Grenoble, France. 11. AOU Policlinico Vittorio Emanuele, Medical Oncology, Catania, Italy. 12. Department of Oncology, University of Torino at Mauriziano Umberto I Hospital, Turin, Italy. 13. Department of Oncology, University of Torino, Turin, Italy giorgio.valabrega@unito.it.
Abstract
BACKGROUND/AIM: Double diagnosis of lung cancer (LC) and ovarian cancer (OC) is rare. Here, we describe patients with synchronous/metachronous LC and OC to identify common clinical and pathological patterns. PATIENTS AND METHODS: Clinical, pathological and molecular data of patients diagnosed and treated at 30 European Institutions from 2008 to 2018 were retrieved and analysed. Whenever tissue was available, centralized pathology revision was performed. RESULTS: A total of 19 cases were found; one was excluded at pathology revision. Most LCs were adenocarcinomas (15/18) and most OCs were high-grade serous (15/18) carcinomas. Of the 9 patients analysed, 7 carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK) and five out of 7 carried BRCA mutations. One patient with a germline-BRCA1 mutation received olaparib, resulting in a durable response of both malignancies. Median overall survival was 33 months. CONCLUSION: In our series, most synchronous/metachronous LCs and OCs showed genetic alterations. Further analyses with wide NGS panel could shed light on the biological mechanisms driving their occurrence. Copyright
BACKGROUND/AIM: Double diagnosis of lung cancer (LC) and ovarian cancer (OC) is rare. Here, we describe patients with synchronous/metachronous LC and OC to identify common clinical and pathological patterns. PATIENTS AND METHODS: Clinical, pathological and molecular data of patients diagnosed and treated at 30 European Institutions from 2008 to 2018 were retrieved and analysed. Whenever tissue was available, centralized pathology revision was performed. RESULTS: A total of 19 cases were found; one was excluded at pathology revision. Most LCs were adenocarcinomas (15/18) and most OCs were high-grade serous (15/18) carcinomas. Of the 9 patients analysed, 7 carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK) and five out of 7 carried BRCA mutations. One patient with a germline-BRCA1 mutation received olaparib, resulting in a durable response of both malignancies. Median overall survival was 33 months. CONCLUSION: In our series, most synchronous/metachronous LCs and OCs showed genetic alterations. Further analyses with wide NGS panel could shed light on the biological mechanisms driving their occurrence. Copyright
Authors: Jenifer L Marks; Ben Golas; Tomas Kirchoff; Vincent A Miller; Gregory J Riely; Kenneth Offit; William Pao Journal: J Thorac Oncol Date: 2008-07 Impact factor: 15.609
Authors: J Remon; D Isla; P Garrido; J de Castro; M Majem; N Viñolas; A Artal; E Carcereny; M R García-Campelo; P Lianes; M Provencio; O Juan; P Diz; R Blanco; R Lopez-Castro; I Maestu; C Vadell; E Felip Journal: Clin Transl Oncol Date: 2017-06-28 Impact factor: 3.405
Authors: Rafael Rosell; Miguel Angel Molina; Carlota Costa; Sara Simonetti; Ana Gimenez-Capitan; Jordi Bertran-Alamillo; Clara Mayo; Teresa Moran; Pedro Mendez; Felipe Cardenal; Dolores Isla; Mariano Provencio; Manuel Cobo; Amelia Insa; Rosario Garcia-Campelo; Noemi Reguart; Margarita Majem; Santiago Viteri; Enric Carcereny; Ruth Porta; Bartomeu Massuti; Cristina Queralt; Itziar de Aguirre; Jose Miguel Sanchez; Maria Sanchez-Ronco; Jose Luis Mate; Aurelio Ariza; Susana Benlloch; Jose Javier Sanchez; Trever G Bivona; Charles L Sawyers; Miquel Taron Journal: Clin Cancer Res Date: 2011-01-13 Impact factor: 12.531
Authors: Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2018-05-29 Impact factor: 508.702
Authors: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245